-DOCSTART- -X- O
Licensed -X- _ O
live -X- _ O
attenuated -X- _ O
virus -X- _ O
vaccines -X- _ O
capable -X- _ O
of -X- _ O
expressing -X- _ O
transgenes -X- _ O
from -X- _ O
other -X- _ O
pathogens -X- _ O
have -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
reduce -X- _ O
the -X- _ O
number -X- _ O
of -X- _ O
childhood -X- _ O
immunizations -X- _ O
by -X- _ O
eliciting -X- _ O
robust -X- _ O
immunity -X- _ O
to -X- _ O
multiple -X- _ O
pathogens -X- _ O
simultaneously. -X- _ O
Recombinant -X- _ B-Intervention
attenuated -X- _ I-Intervention
measles -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
rMV -X- _ I-Intervention
) -X- _ I-Intervention
derived -X- _ O
from -X- _ O
the -X- _ O
Edmonston -X- _ O
Zagreb -X- _ O
vaccine -X- _ O
strain -X- _ O
was -X- _ O
engineered -X- _ O
to -X- _ O
express -X- _ O
simian -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
( -X- _ O
SIV -X- _ O
) -X- _ O
Gag -X- _ O
protein -X- _ O
for -X- _ O
the -X- _ O
purpose -X- _ O
of -X- _ O
evaluating -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
rMV -X- _ O
as -X- _ O
a -X- _ O
vaccine -X- _ O
vector -X- _ O
in -X- _ O
rhesus -X- _ B-Patient
macaques. -X- _ I-Patient
rMV-Gag -X- _ B-Outcome
immunization -X- _ I-Outcome
alone -X- _ I-Outcome
elicited -X- _ I-Outcome
robust -X- _ I-Outcome
measles-specific -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
failed -X- _ I-Outcome
to -X- _ I-Outcome
elicit -X- _ I-Outcome
transgene -X- _ I-Outcome
( -X- _ I-Outcome
Gag -X- _ I-Outcome
) -X- _ I-Outcome
-specific -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
following -X- _ I-Outcome
aerosol -X- _ I-Outcome
or -X- _ I-Outcome
intratracheal -X- _ I-Outcome
/ -X- _ I-Outcome
intramuscular -X- _ I-Outcome
delivery. -X- _ I-Outcome
However -X- _ O
, -X- _ O
when -X- _ O
administered -X- _ O
as -X- _ O
a -X- _ O
priming -X- _ O
vaccine -X- _ O
to -X- _ O
a -X- _ O
heterologous -X- _ O
boost -X- _ O
with -X- _ O
recombinant -X- _ O
adenovirus -X- _ O
serotype -X- _ O
5 -X- _ O
expressing -X- _ O
the -X- _ O
same -X- _ O
transgene -X- _ O
, -X- _ O
rMV-Gag -X- _ O
significantly -X- _ B-Outcome
enhanced -X- _ I-Outcome
Gag-specific -X- _ I-Outcome
T -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
responses -X- _ I-Outcome
following -X- _ I-Outcome
rAd5 -X- _ I-Outcome
immunization. -X- _ I-Outcome
Gag-specific -X- _ B-Outcome
humoral -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
enhanced -X- _ I-Outcome
, -X- _ O
however -X- _ O
, -X- _ O
which -X- _ O
may -X- _ O
be -X- _ O
due -X- _ O
to -X- _ O
either -X- _ O
the -X- _ O
transgene -X- _ O
or -X- _ O
the -X- _ O
vector. -X- _ O
Cellular -X- _ B-Outcome
response -X- _ I-Outcome
priming -X- _ I-Outcome
by -X- _ I-Outcome
rMV -X- _ I-Outcome
against -X- _ I-Outcome
the -X- _ I-Outcome
transgene -X- _ I-Outcome
was -X- _ I-Outcome
highly -X- _ I-Outcome
effective -X- _ I-Outcome
even -X- _ I-Outcome
when -X- _ I-Outcome
using -X- _ I-Outcome
a -X- _ I-Outcome
suboptimal -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
rAd5 -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
boost. -X- _ I-Outcome
These -X- _ O
data -X- _ O
demonstrate -X- _ O
feasibility -X- _ B-Outcome
of -X- _ I-Outcome
using -X- _ I-Outcome
rMV -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
priming -X- _ I-Outcome
component -X- _ I-Outcome
of -X- _ I-Outcome
heterologous -X- _ I-Outcome
prime-boost -X- _ I-Outcome
vaccine -X- _ I-Outcome
regimens -X- _ I-Outcome
for -X- _ I-Outcome
pathogens -X- _ I-Outcome
requiring -X- _ I-Outcome
strong -X- _ I-Outcome
cellular -X- _ I-Outcome
responses -X- _ I-Outcome
. -X- _ O

